文献速递肿瘤 PET/CT

18F-FDG PET/CT较68Ga-FAPI PET/CT更早发现直肠恶性肿瘤

18 F-FDG PET/CT Identified Rectal Malignancy Earlier Than 68 Ga-FAPI PET/CT.
PubMed 文献 · Clin Nucl Med · 2025-03-05

一例69岁食管癌男性在治疗期间接受18F-FDG与68Ga-FAPI双示踪剂PET/CT,基线时两种检查直肠均无异常摄取;3个月后复查时18F-FDG PET/CT显示直肠局灶性摄取,而68Ga-FAPI PET/CT未见异常;17个月后第三次双示踪剂PET/CT示两种检查均于直肠同一区域检出异常活性,术后组织病理证实为腺癌。本例提示18F-FDG PET/CT可比68Ga-FAPI PET/CT更早识别直肠恶性肿瘤。

要点

  • 69岁食管癌男性治疗期间行18F-FDG与68Ga-FAPI双示踪剂PET/CT。
  • 3个月后18F-FDG PET/CT示直肠局灶性摄取,68Ga-FAPI PET/CT未见异常。
  • 17个月后两种PET/CT均检出直肠同一区域异常,术后病理证实为腺癌。

核心结论

  • 本例提示18F-FDG PET/CT可比68Ga-FAPI PET/CT更早识别直肠恶性肿瘤。

研究设计与样本

  • 个案报告:一例69岁食管癌男性在治疗期间接受18F-FDG与68Ga-FAPI双示踪剂PET/CT检查。

主要发现

  • 基线时两种PET/CT均未显示直肠异常摄取。
  • 3个月后18F-FDG PET/CT显示直肠局灶性摄取,而68Ga-FAPI PET/CT未见异常发现。
  • 17个月后第三次双示踪剂PET/CT中,18F-FDG与68Ga-FAPI均检出直肠同一区域的异常活性。
  • 术后组织病理证实该病灶为腺癌。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A 69-year-old man with esophageal cancer underwent dual-tracer PET/CT using 18 F-FDG and 68 Ga-FAPI during his treatment. At baseline, neither scan showed abnormal uptake in the rectum. Three months later, an interim 18 F-FDG PET/CT revealed focal uptake in the rectum, while the 68 Ga-FAPI PET/CT showed no abnormal findings. Seventeen months later, he received a third dual-tracer PET/CT for surveillance. Both 18 F-FDG and 68 Ga-FAPI PET/CT detected abnormal activity in the same area of the rectum . The lesion was later confirmed as adenocarcinoma by histopathology after surgery. Our case demonstrated the 18 F-FDG PET/CT could identify the rectal malignancy before 68 Ga-FAPI PET/CT.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Wang H, Su M. 18 F-FDG PET/CT Identified Rectal Malignancy Earlier Than 68 Ga-FAPI PET/CT. Clin Nucl Med. 2025. PMID: 40042351. doi:10.1097/RLU.0000000000005800

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。